Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

TALAZOPARIB SIGNIFICANTLY EXTENDS PROGRESSION-FREE SURVIVAL IN PHASE 3 EMBRACA TRIAL OF PATIENTS WIT

pfizerDecember 11, 2017

Tag: TALAZOPARIB , Breast Cancer

PharmaSources Customer Service